Market closedNon-fractional
ACADIA Pharmaceuticals/ACAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Ticker
ACAD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
610
Website
www.acadia.com
ACAD Metrics
BasicAdvanced
$3.1B
Market cap
-
P/E ratio
-$0.01
EPS
0.40
Beta
-
Dividend rate
Price and volume
Market cap
$3.1B
Beta
0.4
Financial strength
Current ratio
2.043
Quick ratio
1.726
Long term debt to equity
10.6
Total debt to equity
12.853
Management effectiveness
Return on assets (TTM)
-0.38%
Return on equity (TTM)
-0.41%
Valuation
Price to revenue (TTM)
3.749
Price to book
6.6
Price to tangible book (TTM)
8.65
Price to free cash flow (TTM)
128.913
Growth
Revenue change (TTM)
56.43%
Earnings per share change (TTM)
-98.86%
3-year revenue growth (CAGR)
21.10%
3-year earnings per share growth (CAGR)
-81.49%
What the Analysts think about ACAD
Analyst Ratings
Majority rating from 19 analysts.
ACAD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$206M
-10.91%
Net income
$17M
-63.89%
Profit margin
8.01%
-59.50%
ACAD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.01
-$0.40
$0.28
$0.10
-
Expected
-$0.08
-$0.43
$0.30
$0.05
$0.19
Surprise
-112.10%
-6.13%
-7.85%
113.68%
-
ACAD News
AllArticlesVideos
Acadia Pharmaceuticals: Back In The Buy Zone
Seeking Alpha·1 month ago
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
Business Wire·1 month ago
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $3.1B as of July 27, 2024.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 0 as of July 27, 2024.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ACADIA Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.